PECAM1 and cancer: One of the mechanisms proposed to explain the role of ezetimibe in cancer development and growth is that it may be able to inhibit CD31 (platelet endothelial cell adhesion molecule and increase TSP-1 and SMA) (smooth muscle actin, a perivascular cell marker) expression inhibiting the angiogenesis, promoting apoptosis and preventing cell proliferation.